 |
Prospector
Profile
116-01
|
| |
| Oncologix Tech, Inc. |
NAICS |
334510 |
| 3725 Lawrenceville-Suwanee Rd., Suite B-4
Suwanee, GA 30024 |
Description |
Medical Device Mfg. |
| (770) 831-8818 |
Employees |
9 |
|
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-7.6460 |
| |
Assets |
(mil) |
0.6130 |
| |
Liability |
(mil) |
2.6380 |
| |
(for the year ended 2007-08-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Oncologix Tech, Inc., had a net loss of $1,448,771 for the first quarter ended November 30, 2007, much higher than the $714,622 net loss incurred during the first quarter of 2006. The Company's balance sheet at November 30, 2007, showed an accumulated deficit of $14,706,904 and stockholders' deficit of $2,768,717. It also has strained liquidity with $603,903 in total current assets available to pay $2,208,729 in total current liabilities.
|
| |
|
Intellectual Property:
The Company intends to rely on patent laws, software security measures, license agreements and nondisclosure agreements to protect its exclusive rights under the Master License Agreement with the University of Maryland. Although patents have been applied for the technology underlying the Oncosphere, no patent has yet been granted and there is no assurance that any will be granted or that any part of the technology will be patentable. The Company believes, however, that if patents are issued as applied for, it will have legal protection for the technology that provides the capability of attaching two isotopes, beta emitting for therapy and gamma emitting for imaging or measurement. [SEC Filing 10-KSB 12-14-07]
|
| |
|
Description:
Oncologix Tech, Inc. engages in the research and development of medical devices for the treatment of soft tissue cancers in the United States.
|
| |
|
Officers:
Andre Green (Pres. & CEO); Dr. Steven Kurtzman (VP); Michael A. Kramarz (CFO & Controller)
|
| |
|
Auditor:
Semple, Marchal & Cooper LLP
|
| |
|
Securities:
Common Stock-Symbol OCLG.OB; OTC BB; 71,146,425 common shares outstanding as of January 7, 2008.
|
| |
| |
| |
| return to main page |
|
|
